These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Author: Sasaki S.
    Journal: Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311.
    Abstract:
    Adrenocortical carcinoma is a rare cancer with poor clinical outcomes due to its propensity to transform or relapse. Reported here are 3 cases of adrenocortical carcinoma that were treated between January 2007a nd December 2013. Etoposide, doxorubicin, and cisplatin plus mitotane(EDP plus mitotane)were administered as adjuvant therapy to 1 patient, while the other patients received the therapy upon relapse of their cancers following surgery. One patient experienced PR and another 1 experienced SD during the course of their treatment. While 2 of the patients experienced Grade 3 non-hematological adverse events, all of them experienced Grade 3/4 hematological adverse events. The FIRM-ACT study reported in 2012, proved the effectiveness of EDP plus mitotane for advanced adrenocortical carcinoma, in spite of the several adverse events it caused. Some of the adverse events were severe, resulting in a poor quality of life in the patients. There is not enough evidence to support the use of EDP plus mitotane postoperatively or in recurrent patients. Moreover, due to the rare nature of adrenocortical carcinomas, we don't have enough management cases of EDP plus mitotane chemotherapy for dominant patients. More cases need to be studied to collect sufficient data on the benefits of EDP plus mitotane therapy for adjuvant or relapsed adrenocortical carcinoma.
    [Abstract] [Full Text] [Related] [New Search]